专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06733993B2 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications 失效
标题翻译：增强的第一代腺病毒疫苗表达密码子优化的HIV1-gag，pol，nef和修饰
公开(公告)号：US06733993B2
公开(公告)日：2004-05-11
申请号：US09952060
申请日：2001-09-14
申请人： Emilio A. Emini , Rima Youil , Andrew J. Bett , Ling Chen , David C. Kaslow , John W. Shiver , Timothy J. Toner , Danilo R. Casimiro
发明人： Emilio A. Emini , Rima Youil , Andrew J. Bett , Ling Chen , David C. Kaslow , John W. Shiver , Timothy J. Toner , Danilo R. Casimiro
IPC分类号： C12P2106
CPC分类号： C12N7/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

2. 发明申请

US20070077257A1 Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：增强的第一代腺病毒疫苗表达宽带优化的HIV1-Gag，Pol，Nef和修饰
公开(公告)号：US20070077257A1
公开(公告)日：2007-04-05
申请号：US11604553
申请日：2006-11-27
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： A61K39/00 , A61K39/12
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , C07K14/005 , C12N7/00 , C12N2710/10343 , C12N2710/10351 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, HIV-1 Pol, HIV-1 Nef, and derivatives thereof. The adenoviral vaccines of the present invention, alone or in combination, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：描述了含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的第一代腺病毒载体和基于重组腺病毒的HIV疫苗及其生物学相关的修饰。当直接引入活的脊椎动物组织中时，腺病毒疫苗表达相关蛋白质，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag，HIV-1 Pol，HIV-1 Nef的合成DNA分子及其衍生物。本发明的单独或组合的腺病毒疫苗将对先前未感染的个体提供预防优势，和/或通过减少感染个体内的病毒载量水平提供治疗效果，从而延长HIV-1感染的无症状期。

3. 发明申请

US20050070017A1 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：表达密码子优化的HIV1-Gag，Pol，Nef和修饰的增强的第一代腺病毒疫苗
公开(公告)号：US20050070017A1
公开(公告)日：2005-03-31
申请号：US10636730
申请日：2003-08-07
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： C07K14/16 , C12N7/01 , C12N7/02 , C12N15/861 , A61K39/12 , C12N7/00
CPC分类号： C12N7/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

4. 发明申请

US20070054395A1 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：表达密码子优化的HIV1-Gag，Pol，Nef和修饰的增强的第一代腺病毒疫苗
公开(公告)号：US20070054395A1
公开(公告)日：2007-03-08
申请号：US11599584
申请日：2006-11-13
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： C12Q1/68 , C12N15/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N15/63 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

5. 发明申请

US20130243819A1 Methods Relating To An Attenuated Mycoplasma 有权
标题翻译：关于减毒支原体的方法
公开(公告)号：US20130243819A1
公开(公告)日：2013-09-19
申请号：US13697714
申请日：2011-05-19
申请人： Rima Youil , Youssef Abs El-Osta
发明人： Rima Youil , Youssef Abs El-Osta
IPC分类号： C12N1/36
CPC分类号： C12N1/36 , A61K39/0241 , A61K2039/522 , C07K14/30 , C12Q1/689 , C12Q2600/156
摘要： The present invention provides a method for identifying or generating an attenuated mycoplasma bacterium, which bacterium comprises a mutation in at least one gene as listed and use of the bacterium in a vaccine for eliciting protective immunity against mycoplasma or for detecting infection by said bacterium.
摘要翻译：本发明提供了一种用于鉴定或产生减毒支原体细菌的方法，所述细菌在所列的至少一种基因中的突变和用于引发针对支原体的保护性免疫或用于检测所述细菌感染的疫苗中的细菌的使用。

6. 发明授权

US09260691B2 Methods relating to an attenuated mycoplasma 有权
标题翻译：与减毒支原体有关的方法
公开(公告)号：US09260691B2
公开(公告)日：2016-02-16
申请号：US13697714
申请日：2011-05-19
申请人： Rima Youil , Youssef Abs El-Osta
发明人： Rima Youil , Youssef Abs El-Osta
IPC分类号： A61K39/04 , C07K14/35 , C12N15/00 , C12Q1/00 , C12N1/36 , A61K39/02 , C07K14/30 , C12Q1/68 , A61K39/00
CPC分类号： C12N1/36 , A61K39/0241 , A61K2039/522 , C07K14/30 , C12Q1/689 , C12Q2600/156
摘要： The present invention provides a method for identifying or generating an attenuated mycoplasma bacterium, which bacterium comprises a mutation in at least one gene as listed and use of the bacterium in a vaccine for eliciting protective immunity against mycoplasma or for detecting infection by said bacterium.
摘要翻译：本发明提供了一种用于鉴定或产生减毒支原体细菌的方法，所述细菌在所列的至少一种基因中的突变和用于引发针对支原体的保护性免疫或用于检测所述细菌感染的疫苗中的细菌的使用。

7. 发明授权

US5851770A Detection of mismatches by resolvase cleavage using a magnetic bead support 失效
标题翻译：使用磁珠支撑通过解析酶裂解检测错配
公开(公告)号：US5851770A
公开(公告)日：1998-12-22
申请号：US545404
申请日：1995-10-19
申请人： Jeff Babon , Rima Youil , Jay Stoerker , Anne Huff , Richard G. H. Cotton
发明人： Jeff Babon , Rima Youil , Jay Stoerker , Anne Huff , Richard G. H. Cotton
IPC分类号： C12N15/09 , C12Q1/68
CPC分类号： C12Q1/683 , C12Q1/6888 , C12Q2600/156
摘要： Disclosed is a method for detecting one or more mismatches between a first and a second nucleic acid, the first and second nucleic acids being capable of preferentially hybridizing. The method involves: a) providing the first nucleic acid in its single-stranded form, the first nucleic acid being bound to the first member of a specific binding pair; b) providing the second nucleic acid in its single-stranded form, the second nucleic acid being bound to a detectably labelled reagent; c) contacting the first nucleic acid with the second nucleic acid under conditions allowing heteroduplex formation; d) contacting the product of step (c) with a magnetic bead to which is bound the second member of the specific binding pair under conditions allowing complex formation between the first and the second members of the specific binding pair; e) applying a magnetic field to the mixture to facilitate separation of the magnetic bead from the remainder of the product of step (c); f) contacting the magnetic bead-bound nucleic acid with a resolvase capable of recognizing at least one single base pair mismatch in a heteroduplex, under conditions which permit the resolvase to cleave the heteroduplex; and f) analyzing the product of step (f), the presence of a cleavage product being an indication of a mismatch between the first and second nucleic acids.
摘要翻译：公开了一种用于检测第一和第二核酸之间的一个或多个错配的方法，所述第一和第二核酸能够优先杂交。该方法包括：a）提供其单链形式的第一核酸，第一核酸与特异性结合对的第一个成员结合; b）提供其单链形式的第二核酸，第二核酸与可检测标记的试剂结合; c）在允许异源双链体形成的条件下使第一核酸与第二核酸接触; d）使步骤（c）的产物与限制特异性结合对的第二个成员的磁珠在允许特异性结合对的第一和第二成员之间形成复合物的条件下接触; e）向所述混合物施加磁场以促进磁珠与步骤（c）的产物的其余部分分离; f）使所述磁珠结合的核酸与能够在异源双链体中识别至少一个单碱基对失配的解淀粉酶在允许所述分解酶切割所述异源双链体的条件下接触; 和f）分析步骤（f）的产物，裂解产物的存在是第一和第二核酸之间错配的指示。

8. 发明授权

US5698400A Detection of mutation by resolvase cleavage 失效
标题翻译：通过解析酶裂解检测突变
公开(公告)号：US5698400A
公开(公告)日：1997-12-16
申请号：US714626
申请日：1996-09-16
申请人： Richard G. H. Cotton , Rima Youil , Borries W. Kemper
发明人： Richard G. H. Cotton , Rima Youil , Borries W. Kemper
IPC分类号： G01N33/50 , C12N15/09 , C12Q1/68 , C07H21/04 , C12Q1/70 , C12Q11/34
CPC分类号： C12Q1/6827 , C12Q1/6883 , C12Q1/6886 , C12Q1/689 , C12Q2600/156
摘要： Methods are disclosed for detecting one or more mutations in an isolated test nucleic acid by forming a heteroduplex with a homologous control DNA and contacting the heteroduplex with a resolvase capable of recognizing at least one single base pair mismatch within the heteroduplex. In preferred embodiments of the invention, the resolvase is bacteriophage T4 endonuclease VII.
摘要翻译：公开了用于通过与同源对照DNA形成异源双链体并将异源双链体与能够识别异源双链体内的至少一个单碱基对失配的解析酶接触来检测分离的测试核酸中的一个或多个突变的方法。在本发明的优选实施方案中，解淀粉酶是噬菌体T4内切核酸酶VII。

9. 发明授权

US08524252B2 Temperature sensitive vaccine strain of Mycoplasma hyopneumoniae and uses thereof 有权
标题翻译：猪肺炎支原体感温疫苗株及其用途
公开(公告)号：US08524252B2
公开(公告)日：2013-09-03
申请号：US13321662
申请日：2010-05-19
申请人： Rima Youil , Youssef Abs El-Osta , Glenn Browning , Phillip Markham
发明人： Rima Youil , Youssef Abs El-Osta , Glenn Browning , Phillip Markham
IPC分类号： A61K39/02
CPC分类号： A61K39/0241 , A61K2039/522 , A61K2039/543 , A61K2039/552 , C12R1/35
摘要： The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04/41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses thereof.
摘要翻译：本发明涉及猪肺炎支原体疫苗菌株，其包含在国家测量研究所（澳大利亚）列出或保藏的至少一个基因中的突变，登录号NM04 / 41259，该菌株是温度敏感性和减毒性的疫苗，其包含这种菌株及其方法和用途。

10. 发明申请

US20120135040A1 TEMPERATURE SENSITIVE VACCINE STRAIN OF MYCOPLASMA HYOPNEUMONIAE AND USES THEREOF 有权
标题翻译： MYCOPLASMA HYOPNEUMONIAE的温度敏感性疫苗菌株及其用途
公开(公告)号：US20120135040A1
公开(公告)日：2012-05-31
申请号：US13321662
申请日：2010-05-19
申请人： Rima Youil , Youssef Abs El-Osta , Glenn Browning , Phillip Markham
发明人： Rima Youil , Youssef Abs El-Osta , Glenn Browning , Phillip Markham
IPC分类号： A61K39/02 , A61P37/04 , A61P31/04 , C12N1/21
CPC分类号： A61K39/0241 , A61K2039/522 , A61K2039/543 , A61K2039/552 , C12R1/35
摘要： The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04/41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses thereof.
摘要翻译：本发明涉及猪肺炎支原体疫苗菌株，其包含在国家测量研究所（澳大利亚）列出或保藏的至少一个基因中的突变，登录号NM04 / 41259，该菌株是温度敏感性和减毒性的疫苗，其包含这种菌株及其方法和用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式